Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-78c5997874-j824f Total loading time: 0 Render date: 2024-11-16T09:18:56.477Z Has data issue: false hasContentIssue false

Chapter 18 - The Lewy body dementias

Published online by Cambridge University Press:  01 December 2016

By
Richard R. Murphy  and
James B. Leverenz
Edited by
Bruce L. Miller  and
Bradley F. Boeve
Bruce L. Miller
Affiliation:
University of California, San Francisco
Bradley F. Boeve
Affiliation:
Mayo Clinic, Minnesota
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
The Behavioral Neurology of Dementia , pp. 278 - 300
Publisher: Cambridge University Press
Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

References:

Lewy, F., Zur pathologischen Anatomie der Paralysis agitans. Dtsch Z Nervenheilk, 1913. 50: p. 50–55.Google Scholar
Tretiakoff, C., Contributions a l'Etude de l'Anatomie Pathologique du Locus Niger de Soemmering avec Quelques Deductions Relatives a la Pathogenie des Troubles de Tonus Musculaire et de la Maladie de Parkinson, 1919, Paris: University of Paris.CrossRefGoogle ScholarPubMed
Mamikonyan, E., et al., Mild cognitive impairment is common in Parkinson’s disease patients with normal Mini-Mental State Examination (MMSE) scores. Parkinsonism Relat Disord, 2009. 15(3): p. 226–31.Google Scholar
Troussea, A., Senile trembling and paralysis agitans. Lectures in Clinical Medicine Delivered at the Hotel Dieu, Paris. 1868, London: New Sydenham Society.Google Scholar
Charcot, J.-M., Cinquieme lecon: de la Paralysie Agitante, in Lecons sur les Maladies du Systeme Nerveux Faites a la Salpetriere 1872. Paris.Google Scholar
Charcot, J.-M, and Vulpian, A., De la paralysie agitante. Gaz Hebdomadaire Med Chirurg, 1861; pp. 8–9, 54–59, 765–767, 816–820.Google Scholar
Gowers, W., A Manual of Diseases of the Nervous System. 1886, London: Churchhill.Google Scholar
Lewy, F.H., Die Lehre vom tonus und der Bewegung zugleich systematische Untersuchungen zur Klijik, Physiologie, Pathologie und Pathogenese der Paralysis agitans. 1923, Berlin: Springer.Google Scholar
Hassler, R., Zur Pathologie der Paralysis agitains und des postenzephalitischen parkinsonismus. J Psychol Neurol, 1938. 48: p. 387–476.CrossRefGoogle ScholarPubMed
Woodard, J.S., Concentric hyaline inclusion body formation in mental disease analysis of twenty-seven cases. J Neuropathol Exp Neurol, 1962. 21: p. 442–9.CrossRefGoogle ScholarPubMed
Kosaka, K., Diffuse Lewy body disease in Japan. J Neurol, 1990. 237(3): p. 197–204.CrossRefGoogle ScholarPubMed
Okazaki, H., Lipkin, L.E., and Aronson, S.M., Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neuropathol Exp Neurol, 1961. 20: p. 237–44.CrossRefGoogle ScholarPubMed
Ditter, S.M. and Mirra, S.S., Neuropathologic and clinical features of Parkinson’s disease in Alzheimer’s disease patients. Neurology, 1987. 37(5): p. 754–60.CrossRefGoogle ScholarPubMed
Leverenz, J. and Sumi, S.M., Parkinson’s disease in patients with Alzheimer’s disease. Arch Neurol, 1986. 43(7): p. 662–4.CrossRefGoogle ScholarPubMed
Hansen, L., et al., The Lewy body variant of Alzheimer’s disease: a clinical and pathologic entity. Neurology, 1990. 40(1): p. 1–8.CrossRefGoogle ScholarPubMed
Crystal, H.A., et al., Antemortem diagnosis of diffuse Lewy body disease. Neurology, 1990. 40(10): p. 1523–8.CrossRefGoogle ScholarPubMed
Dickson, D.W., et al., Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer’s disease: light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD. Neurology, 1991. 41(9): p. 1402–9.CrossRefGoogle Scholar
McKeith, I.G., et al., Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. Neurology, 1996. 47(5): p. 1113–24.CrossRefGoogle ScholarPubMed
McKeith, I.G., et al., Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology, 2005. 65(12): p. 1863–72.Google ScholarPubMed
Jellinger, K.A., A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim Biophys Acta, 2009. 1792(7): p. 730–40.CrossRefGoogle ScholarPubMed
Irwin, D.J., et al., Neuropathologic substrates of Parkinson disease dementia. Ann Neurol, 2012. 72(4): p. 587–98.CrossRefGoogle ScholarPubMed
Compta, Y., et al., Lewy- and Alzheimer-type pathologies in Parkinson’s disease dementia: which is more important? Brain, 2011. 134(Pt 5): p. 1493–505.CrossRefGoogle ScholarPubMed
Aarsland, D., et al., Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol, 2003. 60(3): p. 387–92.CrossRefGoogle ScholarPubMed
Aarsland, D., et al., Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology, 2010. 75(12): p. 1062–9.CrossRefGoogle ScholarPubMed
Lippa, C.F., et al., DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology, 2007. 68(11): p. 812–19.CrossRefGoogle ScholarPubMed
Spillantini, M.G., et al., alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy bodies. Proc Natl Acad Sci USA, 1998. 95(11): p. 6469–73.CrossRefGoogle ScholarPubMed
Beyer, K., Domingo-Sabat, M., and Ariza, A., Molecular pathology of Lewy body diseases. Int J Mol Sci, 2009. 10(3): p. 724–45.CrossRefGoogle ScholarPubMed
Uchikado, H., et al., Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol, 2006. 65(7): p. 685–97.CrossRefGoogle ScholarPubMed
Leverenz, J.B., et al., A novel progranulin mutation associated with variable clinical presentation and tau, TDP43 and alpha-synuclein pathology. Brain, 2007. 130(Pt 5): p. 1360–74.CrossRefGoogle ScholarPubMed
Schneider, J.A., et al., Improved detection of substantia nigra pathology in Alzheimer’s disease. J Histochem Cytochem, 2002. 50(1): p. 99–106.CrossRefGoogle ScholarPubMed
Singleton, A. and Gwinn-Hardy, K., Parkinson’s disease and dementia with Lewy bodies: a difference in dose? Lancet, 2004. 364(9440): p. 1105–7.CrossRefGoogle ScholarPubMed
Chartier-Harlin, M.C., et al., Alpha-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet, 2004. 364(9440): p. 1167–9.CrossRefGoogle ScholarPubMed
Polymeropoulos, M.H., et al., Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science, 1997. 276(5321): p. 2045–7.CrossRefGoogle ScholarPubMed
Lippa, C.F., et al., Alpha-synuclein in familial Alzheimer disease: epitope mapping parallels dementia with Lewy bodies and Parkinson disease. Arch Neurol, 2001. 58(11): p. 1817–20.CrossRefGoogle ScholarPubMed
Ahmed, Z., et al., The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol Appl Neurobiol, 2012. 38(1): p. 4–24.CrossRefGoogle ScholarPubMed
Leverenz, J.B., et al., Proteomic identification of novel proteins in cortical Lewy bodies. Brain Pathol, 2007. 17(2): p. 139–45.CrossRefGoogle ScholarPubMed
Markesbery, W.R., et al., Lewy body pathology in normal elderly subjects. J Neuropathol Exp Neurol, 2009. 68(7): p. 816–22.CrossRefGoogle ScholarPubMed
Galvin, J.E., Lee, V.M., and Trojanowski, J.Q., Synucleinopathies: clinical and pathological implications. Arch Neurol, 2001. 58(2): p. 186–90.CrossRefGoogle ScholarPubMed
Hague, K., et al., The distribution of Lewy bodies in pure autonomic failure: autopsy findings and review of the literature. Acta Neuropathol, 1997. 94(2): p. 192–6.CrossRefGoogle ScholarPubMed
Schell, H., et al., Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice. Neuroscience, 2009. 160(4): p. 796–804.CrossRefGoogle ScholarPubMed
Wang, Y., et al., Phosphorylated alpha-synuclein in Parkinson’s disease. Sci Transl Med, 2012. 4(121): p. 121ra20.CrossRefGoogle ScholarPubMed
Marques, O. and Outeiro, T.F., Alpha-synuclein: from secretion to dysfunction and death. Cell Death Dis, 2012. 3: p. e350.CrossRefGoogle ScholarPubMed
Braak, H., et al., Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging, 2003. 24(2): p. 197–211.CrossRefGoogle ScholarPubMed
Leverenz, J.B., et al., Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathol, 2008. 18(2): p. 220–4.CrossRefGoogle ScholarPubMed
Hamilton, R.L., Lewy bodies in Alzheimer’s disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol, 2000. 10(3): p. 378–84.CrossRefGoogle ScholarPubMed
Kraybill, M.L., et al., Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both. Neurology, 2005. 64(12): p. 2069–73.CrossRefGoogle Scholar
Nelson, P.T., et al., Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons. Brain Pathol, 2010. 20(1): p. 66–79.CrossRefGoogle ScholarPubMed
Compta, Y., et al., The significance of alpha-synuclein, amyloid-beta and tau pathologies in Parkinson’s disease progression and related dementia. Neurodegener Dis, 2014;13(2–3):154–6.CrossRefGoogle ScholarPubMed
Irwin, D.J., Lee, V.M., and Trojanowski, J.Q., Parkinson’s disease dementia: convergence of alpha-synuclein, tau and amyloid-beta pathologies. Nat Rev Neurosci, 2013. 14(9): p. 626–36.CrossRefGoogle ScholarPubMed
Tsuang, D., et al., APOE epsilon4 increases risk for dementia in pure synucleinopathies. JAMA Neurol, 2013. 70(2): p. 223–8.CrossRefGoogle ScholarPubMed
Leverenz, J.B., et al., Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype. Arch Neurol, 2006. 63(3): p. 370–6.CrossRefGoogle ScholarPubMed
Hurtig, H.I., et al., Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology, 2000. 54(10): p. 1916–21.CrossRefGoogle ScholarPubMed
Braak, H., et al., Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology, 2005. 64(8): p. 1404–10.CrossRefGoogle ScholarPubMed
Harding, A.J., Broe, G.A., and Halliday, G.M., Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain, 2002. 125(Pt 2): p. 391–403.Google ScholarPubMed
Ho, G.J., et al., Bridging molecular genetics and biomarkers in Lewy body and related disorders. Int J Alzheimers Dis, 2011. 2011: p. 842475.CrossRefGoogle ScholarPubMed
Goedert, M., et al., 100 years of Lewy pathology. Nat Rev Neurol, 2013. 9(1): p. 13–24.CrossRefGoogle Scholar
Yoshita, M., Taki, J., and Yamada, M., A clinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer’s-type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry, 2001. 71(5): p. 583–8.CrossRefGoogle ScholarPubMed
Del Tredici, K. and Braak, H., Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson’s disease-related dementia. J Neurol Neurosurg Psychiatry, 2013. 84(7): p. 774–83.CrossRefGoogle ScholarPubMed
Leverenz, J.B., et al., Increased alpha 2-adrenergic receptor binding in locus coeruleus projection areas in dementia with Lewy bodies. Neurobiol Aging, 2001. 22(4): p. 555–61.CrossRefGoogle ScholarPubMed
Benarroch, E.E., et al., Rostral raphe involvement in Lewy body dementia and multiple system atrophy. Acta Neuropathol, 2007. 114(3): p. 213–20.CrossRefGoogle ScholarPubMed
Boeve, B.F., et al., Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain, 2007. 130(Pt 11): p. 2770–88.CrossRefGoogle ScholarPubMed
Collerton, D., et al., Systematic review and meta-analysis show that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia. Dement Geriatr Cogn Disord, 2003. 16(4): p. 229–37.CrossRefGoogle ScholarPubMed
Walker, Z., et al., Neuropsychological performance in Lewy body dementia and Alzheimer’s disease. Br J Psychiatry, 1997. 170: p. 156–8.Google ScholarPubMed
Mormont, E., et al., The profile of memory disturbance in early Lewy body dementia differs from that in Alzheimer’s disease. Rev Neurol (Paris), 2003. 159(8–9): p. 762–6.CrossRefGoogle ScholarPubMed
Selikhova, M., et al., A clinico-pathological study of subtypes in Parkinson’s disease. Brain, 2009. 132(Pt 11): p. 2947–57.CrossRefGoogle Scholar
Hely, M.A., et al., The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord, 2008. 23(6): p. 837–44.CrossRefGoogle ScholarPubMed
Jicha, G.A., et al., Prodromal clinical manifestations of neuropathologically confirmed Lewy body disease. Neurobiol Aging, 2010. 31(10): p. 1805–13.CrossRefGoogle ScholarPubMed
Molano, J., et al., Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study. Brain, 2010. 133(Pt 2): p. 540–56.Google ScholarPubMed
Litvan, I., et al., Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord, 2012. 27(3): p. 349–56.CrossRefGoogle ScholarPubMed
Aarsland, D., et al., Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology, 2009. 72(13): p. 1121–6.CrossRefGoogle Scholar
Williams-Gray, C.H., et al., Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain, 2007. 130(Pt 7): p. 1787–98.CrossRefGoogle ScholarPubMed
Janvin, C.C., et al., Subtypes of mild cognitive impairment in Parkinson’s disease: progression to dementia. Mov Disord, 2006. 21(9): p. 1343–9.CrossRefGoogle ScholarPubMed
Woods, S.P. and Troster, A.I., Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson’s disease. J Int Neuropsychol Soc, 2003. 9(1): p. 17–24.CrossRefGoogle ScholarPubMed
Cholerton, B.A., et al., Evaluation of mild cognitive impairment subtypes in Parkinson’s disease. Mov Disord, 2014. 29(6): p. 756–64.CrossRefGoogle ScholarPubMed
Ballard, C., et al., Attention and fluctuating attention in patients with dementia with Lewy bodies and Alzheimer disease. Arch Neurol, 2001. 58(6): p. 977–82.CrossRefGoogle ScholarPubMed
Walker, M.P., et al., Quantifying fluctuation in dementia with Lewy bodies, Alzheimer’s disease, and vascular dementia. Neurology, 2000. 54(8): p. 1616–25.CrossRefGoogle ScholarPubMed
Cummings, J.L., Fluctuations in cognitive function in dementia with Lewy bodies. Lancet Neurol, 2004. 3(5): p. 266.CrossRefGoogle ScholarPubMed
Walker, M.P., et al., The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia. Br J Psychiatry, 2000. 177: p. 252–6.CrossRefGoogle ScholarPubMed
Ferman, T.J., et al., DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology, 2004. 62(2): p. 181–7.CrossRefGoogle ScholarPubMed
Ferman, T.J., et al., Abnormal daytime sleepiness in dementia with Lewy bodies compared to Alzheimer’s disease using the Multiple Sleep Latency Test. Alzheimers Res Ther, 2014. 6(9): p. 76.CrossRefGoogle ScholarPubMed
Sonnen, J.A., et al., Ecology of the aging human brain. Arch Neurol, 2011. 68(8): p. 1049–56.CrossRefGoogle ScholarPubMed
Ylikoski, R., et al., Cardiovascular diseases, health status, brain imaging findings and neuropsychological functioning in neurologically healthy elderly individuals. Arch Gerontol Geriatr, 2000. 30(2): p. 115–30.CrossRefGoogle ScholarPubMed
Knopman, D., et al., Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology, 2001. 56(1): p. 42–8.CrossRefGoogle ScholarPubMed
Saxby, B.K., et al., Effects of hypertension on attention, memory, and executive function in older adults. Health Psychol, 2003. 22(6): p. 587–91.CrossRefGoogle ScholarPubMed
Burdick, D.J., et al., People with Parkinson’s disease and normal MMSE score have a broad range of cognitive performance. Mov Disord, 2014. 29(10): p. 1258–64.CrossRefGoogle ScholarPubMed
Wang, C.S., et al., Montreal Cognitive Assessment and Mini-Mental State Examination performance in patients with mild-to-moderate dementia with Lewy bodies, Alzheimer’s disease, and normal participants in Taiwan. Int Psychogeriatr, 2013. 25(11): p. 1839–48.CrossRefGoogle ScholarPubMed
Nelson, P.T., et al., Relative preservation of MMSE scores in autopsy-proven dementia with Lewy bodies. Neurology, 2009. 73(14): p. 1127–33.3.0.CO;2-5>CrossRefGoogle ScholarPubMed
Del Ser, T., et al., Dementia with Lewy bodies: findings from an international multicentre study. Int J Geriatr Psychiatry, 2000. 15(11): p. 1034–45.Google ScholarPubMed
Cummings, J.L., et al., neuropsychiatric syndromes in neurodegenerative disease: frequency and signficance. Semin Clin Neuropsychiatry, 1996. 1(4): p. 241–247.CrossRefGoogle ScholarPubMed
Ballard, C., et al., Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer’s disease. Am J Psychiatry, 1999. 156(7): p. 1039–45.CrossRefGoogle ScholarPubMed
McShane, R., et al., Prospective study of relations between cortical Lewy bodies, poor eyesight, and hallucinations in Alzheimer’s disease. J Neurol Neurosurg Psychiatry, 1995. 59(2): p. 185–8.CrossRefGoogle ScholarPubMed
Aarsland, D., et al., Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol, 1999. 56(5): p. 595–601.CrossRefGoogle Scholar
Merims, D., et al., Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson’s disease. J Neural Transm, 2004. 111(10–11): p. 1447–53.CrossRefGoogle Scholar
Goetz, C.G., et al., The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol, 2006. 63(5): p. 713–6.CrossRefGoogle ScholarPubMed
Rosen, H.J., Anosognosia in neurodegenerative disease. Neurocase, 2011. 17(3): p. 231–41.CrossRefGoogle ScholarPubMed
Uc, E.Y., et al., Real-life driving outcomes in Parkinson disease. Neurology, 2011. 76(22): p. 1894–902.CrossRefGoogle ScholarPubMed
Gotham, A.M., Brown, R.G., and Marsden, C.D., Depression in Parkinson’s disease: a quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry, 1986. 49(4): p. 381–9.Google ScholarPubMed
Burn, D.J., et al., Extrapyramidal features in Parkinson’s disease with and without dementia and dementia with Lewy bodies: A cross-sectional comparative study. Mov Disord, 2003. 18(8): p. 884–9.CrossRefGoogle ScholarPubMed
Kao, A.W., et al., Cognitive and neuropsychiatric profile of the synucleinopathies: Parkinson disease, dementia with Lewy bodies, and multiple system atrophy. Alzheimer Dis Assoc Disord, 2009. 23(4): p. 365–70.CrossRefGoogle ScholarPubMed
Ravina, B., et al., The impact of depressive symptoms in early Parkinson disease. Neurology, 2007. 69(4): p. 342–7.CrossRefGoogle ScholarPubMed
Odenheimer, G., et al., Quality improvement in neurology: dementia management quality measures (executive summary). Am J Occup Ther, 2013. 67(6): p. 704–10.CrossRefGoogle ScholarPubMed
Odenheimer, G., et al., Quality improvement in neurology: dementia management quality measures. J Am Geriatr Soc, 2014. 62(3): p. 558–61.CrossRefGoogle ScholarPubMed
Weintraub, D., et al., Screening for impulse control symptoms in patients with de novo Parkinson disease: a case-control study. Neurology, 2013. 80(2): p. 176–80.CrossRefGoogle ScholarPubMed
Balarajah, S. and Cavanna, A.E., The pathophysiology of impulse control disorders in Parkinson disease. Behav Neurol, 2013. 26(4): p. 237–44.CrossRefGoogle ScholarPubMed
Louis, E.D., et al., Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson’s disease. Neurology, 1997. 48(2): p. 376–80.Google ScholarPubMed
Weiner, M.F., et al., Alzheimer’s disease and its Lewy body variant: a clinical analysis of postmortem verified cases. Am J Psychiatry, 1996. 153(10): p. 1269–73.CrossRefGoogle ScholarPubMed
Aarsland, D., et al., Neuroleptic sensitivity in Parkinson’s disease and Parkinsonian dementias. J Clin Psychiatry, 2005. 66(5): p. 633–7.Google ScholarPubMed
Baskys, A., Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms. J Clin Psychiatry, 2004. 65 (Suppl 11): p. 16–22.CrossRefGoogle ScholarPubMed
Boeve, B.F., REM sleep behavior disorder: Updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann N Y Acad Sci, 2010. 1184: p. 15–54.CrossRefGoogle ScholarPubMed
Boeve, B.F., et al., Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med, 2013. 14(8): p. 754–62.CrossRefGoogle ScholarPubMed
Friedman, J.H., Fernandez, H.H., and Sudarsky, L.R., REM behavior disorder and excessive daytime somnolence in Machado-Joseph disease (SCA-3). Mov Disord, 2003. 18(12): p. 1520–2.CrossRefGoogle ScholarPubMed
Gagnon, J.F., et al., Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases. Lancet Neurol, 2006. 5(5): p. 424–32.CrossRefGoogle ScholarPubMed
Schenck, C.H., Bundlie, S.R., and Mahowald, M.W., Delayed emergence of a Parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology, 1996. 46(2): p. 388–93.CrossRefGoogle Scholar
Zesiewicz, T.A., et al., Practice parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 2010. 74(11): p. 924–31.CrossRefGoogle ScholarPubMed
Stubendorff, K., et al., The impact of autonomic dysfunction on survival in patients with dementia with Lewy bodies and Parkinson’s disease with dementia. PLoS One, 2012. 7(10): p. e45451.Google ScholarPubMed
Allan, L.M., et al., Autonomic dysfunction in dementia. J Neurol Neurosurg Psychiatry, 2007. 78(7): p. 671–7.CrossRefGoogle ScholarPubMed
Thaisetthawatkul, P., et al., Autonomic dysfunction in dementia with Lewy bodies. Neurology, 2004. 62(10): p. 1804–9.CrossRefGoogle ScholarPubMed
Ferreira, D., et al., Meta-review of CSF core biomarkers in Alzheimer’s disease: The state-of-the-art after the new revised diagnostic criteria. Front Aging Neurosci, 2014. 6: p. 47.CrossRefGoogle ScholarPubMed
Siderowf, A., et al., CSF amyloid {beta} 1–42 predicts cognitive decline in Parkinson disease. Neurology, 2010. 75(12): p. 1055–61.CrossRefGoogle ScholarPubMed
Hong, Z., et al., DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain, 2010. 133(Pt 3): p. 713–26.CrossRefGoogle ScholarPubMed
Kasuga, K., et al., Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer’s disease. J Neurol Neurosurg Psychiatry, 2010. 81(6): p. 608–10.CrossRefGoogle ScholarPubMed
Shi, M., et al., Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol, 2011. 69(3): p. 570–80.CrossRefGoogle ScholarPubMed
Aerts, M.B., et al., CSF tau, Abeta42, and MHPG differentiate dementia with Lewy bodies from Alzheimer’s disease. J Alzheimers Dis, 2011. 27(2): p. 377–84.Google ScholarPubMed
Kang, J.H., et al., Association of cerebrospinal fluid beta-amyloid 1–42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol, 2013. 70(10): p. 1277–87.CrossRefGoogle ScholarPubMed
Parnetti, L., et al., Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol, 2013. 9(3): p. 131–40.CrossRefGoogle ScholarPubMed
Barber, R., et al., MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology, 2000. 54(6): p. 1304–9.CrossRefGoogle ScholarPubMed
Imamura, T., et al., Occipital glucose metabolism in dementia with Lewy bodies with and without parkinsonism: a study using positron emission tomography. Dement Geriatr Cogn Disord, 2001. 12(3): p. 194–7.CrossRefGoogle ScholarPubMed
Antonini, A., et al., Perfusion ECD/SPECT in the characterization of cognitive deficits in Parkinson’s disease. Neurol Sci, 2001. 22(1): p. 45–6.CrossRefGoogle ScholarPubMed
Colloby, S.J., et al., A comparison of (99m)Tc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer’s disease using statistical parametric mapping. Eur J Nucl Med Mol Imaging, 2002. 29(5): p. 615–22.CrossRefGoogle ScholarPubMed
Firbank, M.J., et al., Regional cerebral blood flow in Parkinson’s disease with and without dementia. Neuroimage, 2003. 20(2): p. 1309–19.CrossRefGoogle ScholarPubMed
Pasquier, J., et al., Value of (99m)Tc-ECD SPET for the diagnosis of dementia with Lewy bodies. Eur J Nucl Med Mol Imaging, 2002. 29(10): p. 1342–8.CrossRefGoogle ScholarPubMed
Fujishiro, H., et al., Diffuse occipital hypometabolism on [18 F]-FDG PET scans in patients with idiopathic REM sleep behavior disorder: prodromal dementia with Lewy bodies? Psychogeriatrics, 2010. 10(3): p. 144–52.CrossRefGoogle ScholarPubMed
Firbank, M.J., et al., Longitudinal study of cerebral blood flow SPECT in Parkinson’s disease with dementia, and dementia with Lewy bodies. Int J Geriatr Psychiatry, 2005. 20(8): p. 776–82.CrossRefGoogle ScholarPubMed
Ba, F. and Martin, W.R., Dopamine transporter imaging as a diagnostic tool for parkinsonism and related disorders in clinical practice. Parkinsonism Relat Disord, 2015. 21(2): p. 87–94.CrossRefGoogle ScholarPubMed
Langer, A., et al., Metaiodobenzylguanidine imaging in diabetes mellitus: assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia. J Am Coll Cardiol, 1995. 25(3): p. 610–8.Google ScholarPubMed
Merlet, P., et al., Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med, 1999. 40(6): p. 917–23.CrossRefGoogle ScholarPubMed
Davies, P. and Maloney, A.J., Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet, 1976. 2(8000): p. 1403.CrossRefGoogle ScholarPubMed
Tiraboschi, P., et al., Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease. Arch Gen Psychiatry, 2002. 59(10): p. 946–51.CrossRefGoogle ScholarPubMed
McKeith, I., et al., Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet, 2000. 356(9247): p. 2031–6.CrossRefGoogle Scholar
Wesnes, K.A., et al., Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the cognitive drug research computerised assessment system. Dement Geriatr Cogn Disord, 2002. 13(3): p. 183–92.CrossRefGoogle ScholarPubMed
Ikeda, M., et al., Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial. Alzheimers Res Ther, 2015. 7(1): p. 4.CrossRefGoogle ScholarPubMed
Mori, E., et al., Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol, 2012. 72(1): p. 41–52.CrossRefGoogle ScholarPubMed
Francis, P.T. and Perry, E.K., Cholinergic and other neurotransmitter mechanisms in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies. Mov Disord, 2007. 22 (Suppl 17): p. S351–7.CrossRefGoogle ScholarPubMed
Emre, M., et al., Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med, 2004. 351(24): p. 2509–18.CrossRefGoogle ScholarPubMed
Dubois, B., et al., Donepezil in Parkinson’s disease dementia: a randomized, double-blind efficacy and safety study. Mov Disord, 2012. 27(10): p. 1230–8.CrossRefGoogle Scholar
Miyasaki, J.M., et al., Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 2006. 66(7): p. 996–1002.CrossRefGoogle ScholarPubMed
Emre, M., et al., Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol, 2010. 9(10): p. 969–77.CrossRefGoogle ScholarPubMed
Aarsland, D., et al., Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol, 2009. 8(7): p. 613–8.CrossRefGoogle ScholarPubMed
O'Donnell, B.F., et al., Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol, 1992. 5(1): p. 45–52.CrossRefGoogle ScholarPubMed
Cummings, J.L., et al., Efficacy of olanzapine in the treatment of psychosis in dementia with Lewy bodies. Dement Geriatr Cogn Disord, 2002. 13(2): p. 67–73.CrossRefGoogle ScholarPubMed
Goetz, C.G., et al., Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology, 2000. 55(6): p. 789–94.CrossRefGoogle ScholarPubMed
Morgante, L., et al., Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson’s disease. Neurol Sci, 2002. 23 (Suppl 2): p. S89–90.CrossRefGoogle ScholarPubMed
Fernandez, H.H., Trieschmann, M.E., and Friedman, J.H., Treatment of psychosis in Parkinson’s disease: safety considerations. Drug Saf, 2003. 26(9): p. 643–59.CrossRefGoogle ScholarPubMed
Fernandez, H.H., et al., Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov Disord, 2003. 18(5): p. 510–14.CrossRefGoogle ScholarPubMed
Fernandez, H.H., et al., Quetiapine for psychosis in Parkinson’s disease versus dementia with Lewy bodies. J Clin Psychiatry, 2002. 63(6): p. 513–15.CrossRefGoogle ScholarPubMed
Fernandez, H.H., Wu, C.K., and Ott, B.R., Pharmacotherapy of dementia with Lewy bodies. Expert Opin Pharmacother, 2003. 4(11): p. 2027–37.CrossRefGoogle ScholarPubMed
Cummings, J., et al., Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet, 2014. 383(9916): p. 533–40.CrossRefGoogle Scholar
Aarsland, D., et al., Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 2007. 68(1): p. 80; author reply 81.CrossRefGoogle ScholarPubMed
Aarsland, D., Taylor, J.P., and Weintraub, D., Psychiatric issues in cognitive impairment. Mov Disord, 2014. 29(5): p. 651–62.CrossRefGoogle ScholarPubMed
Richard, I.H., et al., A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology, 2012. 78(16): p. 1229–36.CrossRefGoogle ScholarPubMed
Brodaty, H., Antidepressant treatment in Alzheimer’s disease. Lancet, 2011. 378(9789): p. 375–6.CrossRefGoogle ScholarPubMed
Pollock, B.G., et al., A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry, 2007. 15(11): p. 942–52.CrossRefGoogle ScholarPubMed
Molloy, S., et al., The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry, 2005. 76(9): p. 1200–3.CrossRefGoogle ScholarPubMed
McCarter, S.J., et al., Treatment outcomes in REM sleep behavior disorder. Sleep Med, 2013. 14(3): p. 237–42.CrossRefGoogle ScholarPubMed
Kay, G.G. and Ebinger, U., Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract, 2008. 62(11): p. 1792–800.CrossRefGoogle ScholarPubMed
Staskin, D., et al., Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract, 2010. 64(9): p. 1294–300.CrossRefGoogle ScholarPubMed
Bridgeman, M.B., et al., Mirabegron: beta3-adrenergic receptor agonist for the treatment of overactive bladder. Ann Pharmacother, 2013. 47(7–8): p. 1029–38.CrossRefGoogle ScholarPubMed
Duda, J.E., Pathology and neurotransmitter abnormalities of dementia with Lewy bodies. Dement Geriatr Cogn Disord, 2004. 17 (Suppl 1): p. 3–14.CrossRefGoogle ScholarPubMed
Perry, E.K., et al., Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson’s and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord, 1993. 7(2): p. 69–79.CrossRefGoogle ScholarPubMed
Walker, Z., et al., Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology, 2004. 62(9): p. 1568–72.Google ScholarPubMed
Bertrand, E., et al., Qualitative and quantitative analysis of locus coeruleus neurons in Parkinson’s disease. Folia Neuropathol, 1997. 35(2): p. 80–6.CrossRefGoogle ScholarPubMed
Zgaljardic, D.J., Foldi, N.S., and Borod, J.C., Cognitive and behavioral dysfunction in Parkinson’s disease: neurochemical and clinicopathological contributions. J Neural Transm, 2004. 111(10–11): p. 1287–301.CrossRefGoogle ScholarPubMed
Meeus, B., Theuns, J., and Van Broeckhoven, C., The genetics of dementia with Lewy bodies: what are we missing? Arch Neurol, 2012. 69(9): p. 1113–18.CrossRefGoogle ScholarPubMed
Klein, C. and Westenberger, A., Genetics of Parkinson’s disease. Cold Spring Harb Perspect Med, 2012. 2(1): p. a008888.CrossRefGoogle ScholarPubMed
Conway, K.A., Harper, J.D., and Lansbury, P.T., Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med, 1998. 4(11): p. 1318–20.CrossRefGoogle ScholarPubMed
Zarranz, J.J., et al., The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol, 2004. 55(2): p. 164–73.CrossRefGoogle ScholarPubMed
Nishioka, K., et al., Association of alpha-, beta-, and gamma-synuclein with diffuse Lewy body disease. Arch Neurol, 2010. 67(8): p. 970–5.CrossRefGoogle ScholarPubMed
Ohtake, H., et al., Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology, 2004. 63(5): p. 805–11.CrossRefGoogle ScholarPubMed
Chung, K.K., et al., Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med, 2001. 7(10): p. 1144–50.CrossRefGoogle Scholar
Pramstaller, P.P., et al., Lewy body Parkinson’s disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol, 2005. 58(3): p. 411–22.CrossRefGoogle Scholar
Ruffmann, C., et al., Lewy body pathology and typical Parkinson disease in a patient with a heterozygous (R275W) mutation in the Parkin gene (PARK2). Acta Neuropathol, 2012. 123(6): p. 901–3.CrossRefGoogle ScholarPubMed
Sharp, M.E., et al., Parkinson’s disease with Lewy bodies associated with a heterozygous PARKIN dosage mutation. Mov Disord, 2014. 29(4): p. 566–8.CrossRefGoogle ScholarPubMed
Paisan-Ruiz, C., Lewis, P.A., and Singleton, A.B., LRRK2: cause, risk, and mechanism. J Parkinsons Dis, 2013. 3(2): p. 85–103.CrossRefGoogle ScholarPubMed
Healy, D.G., et al., Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case-control study. Lancet Neurol, 2008. 7(7): p. 583–90.CrossRefGoogle ScholarPubMed
Meeus, B., et al., Comprehensive genetic and mutation analysis of familial dementia with Lewy bodies linked to 2q35-q36. J Alzheimers Dis, 2010. 20(1): p. 197–205.CrossRefGoogle ScholarPubMed
Tsuang, D.W., DiGiacomo, L., and Bird, T.D., Familial occurrence of dementia with Lewy bodies. Am J Geriatr Psychiatry, 2004. 12(2): p. 179–88.CrossRefGoogle ScholarPubMed
Bonner, L.T., et al., Familial dementia with Lewy bodies with an atypical clinical presentation. J Geriatr Psychiatry Neurol, 2003. 16(1): p. 59–64.CrossRefGoogle ScholarPubMed
Tsuang, D.W., et al., Familial dementia with Lewy bodies: a clinical and neuropathological study of 2 families. Arch Neurol, 2002. 59(10): p. 1622–30.CrossRefGoogle ScholarPubMed
Galvin, J.E., et al., Familial dementia with Lewy bodies: clinicopathologic analysis of two kindreds. Neurology, 2002. 59(7): p. 1079–82.Google ScholarPubMed
Ohara, K., et al., Familial dementia with Lewy bodies (DLB). Clin Neuropathol, 1999. 18(5): p. 232–9.CrossRefGoogle ScholarPubMed
Harding, A.J., et al., Identification of families with cortical Lewy body disease. Am J Med Genet B Neuropsychiatr Genet, 2004. 128B(1): p. 118–22.CrossRefGoogle ScholarPubMed
Sidransky, E., et al., Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med, 2009. 361(17): p. 1651–61.CrossRefGoogle ScholarPubMed
Tsuang, D., et al., GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology, 2012. 79(19): p. 1944–50.CrossRefGoogle ScholarPubMed
Nalls, M.A., et al., A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol, 2013. 70(6): p. 727–35.CrossRefGoogle ScholarPubMed
Mata, I.F., et al., Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. Arch Neurol, 2008. 65(3): p. 379–82.CrossRefGoogle Scholar
Seto-Salvia, N., et al., Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson’s disease course. Mov Disord, 2012. 27(3): p. 393–9.CrossRefGoogle ScholarPubMed
Alcalay, R.N., et al., Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology, 2012. 78(18): p. 1434–40.CrossRefGoogle Scholar
Winder-Rhodes, S.E., et al., Glucocerebrosidase mutations influence the natural history of Parkinson’s disease in a community-based incident cohort. Brain, 2013. 136(Pt 2): p. 392–9.CrossRefGoogle ScholarPubMed
Leverenz, J.B., Lopez, O.L., and Dekosky, S.T., The expanding role of genetics in the Lewy body diseases: the glucocerebrosidase gene. Arch Neurol, 2009. 66(5): p. 555–6.CrossRefGoogle ScholarPubMed
Galvin, J.E., et al., Axon pathology in Parkinson’s disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Proc Natl Acad Sci USA, 1999. 96(23): p. 13450–5.CrossRefGoogle ScholarPubMed
Minami, A., et al., Function of alpha-synuclein and PINK1 in Lewy body dementia (Review). Int J Mol Med, 2015. 35(1): p. 3–9.CrossRefGoogle ScholarPubMed
Beyer, K. and Ariza, A., Alpha-synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration. Mol Neurobiol, 2013. 47(2): p. 509–24.CrossRefGoogle ScholarPubMed
Xiang, W., et al., Oxidative stress-induced posttranslational modifications of alpha-synuclein: specific modification of alpha-synuclein by 4-hydroxy-2-nonenal increases dopaminergic toxicity. Mol Cell Neurosci, 2013. 54: p. 71–83.CrossRefGoogle ScholarPubMed
Bendor, J.T., Logan, T.P., and Edwards, R.H., The function of alpha-synuclein. Neuron, 2013. 79(6): p. 1044–66.CrossRefGoogle ScholarPubMed
Visanji, N.P., et al., The prion hypothesis in Parkinson’s disease: Braak to the future. Acta Neuropathol Commun, 2013. 1(1): p. 2.CrossRefGoogle ScholarPubMed
Li, J.Y., et al., Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat Med, 2008. 14(5): p. 501–3.CrossRefGoogle ScholarPubMed
Chu, Y. and Kordower, J.H., Lewy body pathology in fetal grafts. Ann N Y Acad Sci, 2010. 1184: p. 55–67.CrossRefGoogle ScholarPubMed
Kahle, P.J., et al., Physiology and pathophysiology of alpha-synuclein. Cell culture and transgenic animal models based on a Parkinson’s disease-associated protein. Ann N Y Acad Sci, 2000. 920: p. 33–41.CrossRefGoogle ScholarPubMed
Nuber, S., et al., Environmental neurotoxic challenge of conditional alpha-synuclein transgenic mice predicts a dopaminergic olfactory-striatal interplay in early PD. Acta Neuropathol, 2014. 127(4): p. 477–94.CrossRefGoogle ScholarPubMed
Tian, T., et al., TDP-43 potentiates alpha-synuclein toxicity to dopaminergic neurons in transgenic mice. Int J Biol Sci, 2011. 7(2): p. 234–43.CrossRefGoogle ScholarPubMed
Casadei, N., et al., Overexpression of synphilin-1 promotes clearance of soluble and misfolded alpha-synuclein without restoring the motor phenotype in aged A30P transgenic mice. Hum Mol Genet, 2014. 23(3): p. 767–81.CrossRefGoogle ScholarPubMed
Fournier, M., et al., Parkin depletion delays motor decline dose-dependently without overtly affecting neuropathology in alpha-synuclein transgenic mice. BMC Neurosci, 2013. 14: p. 135.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×